Repligen Corporation (NASDAQ:RGEN) went down by -9.19% from its latest closing price compared to the recent 1-year high of $327.32. The company’s stock price has collected -11.64% of loss in the last five trading sessions. Press Release reported on 12/30/21 that Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
Is It Worth Investing in Repligen Corporation (NASDAQ :RGEN) Right Now?
Repligen Corporation (NASDAQ:RGEN) scored a price-to-earnings ratio above its average ratio, recording 91.48 x from its present earnings ratio. Plus, the 36-month beta value for RGEN is at 0.82. Opinions of the stock are interesting as 8 analysts out of 9 who provided ratings for Repligen Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $321.63, which is $121.0 above the current price. RGEN currently public float of 51.52M and currently shorts hold a 2.92% ratio of that float. Today, the average trading volume of RGEN was 408.37K shares.
RGEN’s Market Performance
RGEN stocks went down by -11.64% for the week, with a monthly drop of -24.14% and a quarterly performance of -28.67%, while its annual performance rate touched -9.75%. The volatility ratio for the week stands at 6.19% while the volatility levels for the past 30 days are set at 5.57% for Repligen Corporation. The simple moving average for the period of the last 20 days is -22.13% for RGEN stocks with a simple moving average of -19.91% for the last 200 days.
Analysts’ Opinion of RGEN
Many brokerage firms have already submitted their reports for RGEN stocks, with Exane BNP Paribas repeating the rating for RGEN by listing it as a “Outperform.” The predicted price for RGEN in the upcoming period, according to Exane BNP Paribas is $330 based on the research report published on October 14th of the previous year 2021.
KeyBanc Capital Markets, on the other hand, stated in their research note that they expect to see RGEN reach a price target of $241. The rating they have provided for RGEN stocks is “Overweight” according to the report published on November 10th, 2020.
H.C. Wainwright gave a rating of “Buy” to RGEN, setting the target price at $168 in the report published on August 24th of the previous year.
RGEN Trading at -26.54% from the 50-Day Moving Average
After a stumble in the market that brought RGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.48% of loss for the given period.
Volatility was left at 5.57%, however, over the last 30 days, the volatility rate increased by 6.19%, as shares sank -26.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.72% lower at present.
During the last 5 trading sessions, RGEN fell by -11.64%, which changed the moving average for the period of 200-days by -1.47% in comparison to the 20-day moving average, which settled at $242.49. In addition, Repligen Corporation saw -27.67% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at RGEN starting from Hunt Anthony, who sale 17,355 shares at the price of $276.85 back on Nov 18. After this action, Hunt Anthony now owns 182,140 shares of Repligen Corporation, valued at $4,804,674 using the latest closing price.
DAWES KAREN A, the Director of Repligen Corporation, sale 4,783 shares at $263.93 during a trade that took place back on Nov 10, which means that DAWES KAREN A is holding 91,247 shares at $1,262,355 based on the most recent closing price.
Stock Fundamentals for RGEN
Current profitability levels for the company are sitting at:
- +22.19 for the present operating margin
- +53.06 for the gross margin
The net margin for Repligen Corporation stands at +16.36. The total capital return value is set at 5.20, while invested capital returns managed to touch 4.17. Equity return is now at value 7.40, with 5.90 for asset returns.
Based on Repligen Corporation (RGEN), the company’s capital structure generated 18.01 points at debt to equity in total, while total debt to capital is 15.26. Total debt to assets is 14.47, with long-term debt to equity ratio resting at 1.73. Finally, the long-term debt to capital ratio is 1.46.
When we switch over and look at the enterprise to sales, we see a ratio of 18.93, with the company’s debt to enterprise value settled at 0.03. The receivables turnover for the company is 6.37 and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.83.